Format

Send to

Choose Destination
See comment in PubMed Commons below
Ther Adv Endocrinol Metab. 2014 Apr;5(2):34-8. doi: 10.1177/2042018814543483.

Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis.

Author information

1
Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut- Medical Center, New York, USA.
2
Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017, USA.

Abstract

Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis.

KEYWORDS:

dipeptidyl peptidase-4 inhibitors; glucagon-like peptide-1; glycemic control; incretin; liraglutide; metabolic syndrome; obesity; psoriasis; type 2 diabetes

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center